News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accuray Inc. (ARAY)'s CyberKnife and TomoTherapy Highlighted at World Conference on Lung Cancer


7/7/2011 7:47:50 AM

SUNNYVALE, Calif., July 7, 2011 /PRNewswire/ --Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced new clinical data highlighting the ability of its CyberKnife® Robotic Radiosurgery System and its TomoTherapy® Radiation Therapy System to treat a wide range of patients with lung cancer and lung metastases. The new outcome data was presented at the 14th World Conference on Lung Cancer, the leading global forum for lung cancer and thoracic oncology research and practice, which took place July 3-7, 2011 in Amsterdam, The Netherlands.

The CyberKnife System, with its unique tracking and robotic correcting capabilities, is a dedicated radiosurgery system able to deliver destructive doses of radiation to tumors throughout the lung with the highest levels of accuracy, even for tumors close to critical structures such as the heart and esophagus. The TomoTherapy system has the ability to deliver both high quality intensity modulated radiation therapy for larger, complex tumors and ablative doses of radiation for smaller peripheral lung tumors that are away from critical structures, making it the premier hybrid radiation therapy system.

"The data presented this week at the World Conference on Lung Cancer demonstrate that CyberKnife and TomoTherapy deliver best-in-class radiation treatment options for a wide range of lung cancer patients," said Euan S. Thomson, Ph.D., president and chief executive officer of Accuray. "The unsurpassed flexibility of these systems, combined with a growing body of clinical evidence demonstrating low toxicity and long-term tumor control, make Accuray's technologies increasingly critical tools in treatment of even the most complex and advanced lung cancers."

Highlights of the research include:

Two studies from The Netherlands that provide data on the ability of the TomoTherapy System and the CyberKnife System to deliver stereotactic body radiotherapy (SBRT) for primary lung cancer and lung metastases.

The first, a study of 89 patients treated with the TomoTherapy System at the Radiotherapeutisch Instituut Stedendriehoek en Omstreken (RISO) in Deventer, The Netherlandsa public, independent institute offering radiation therapy for multiple hospitals in the regionfound high rates of local tumor control with low levels of toxicity in a heterogeneous group of patients, many of whom had undergone previous surgery or conventional radiation therapy. In this study, two-year local progression free survival was 95 percent. This data suggests that image-guided SBRT with TomoTherapy provided an effective treatment option for this challenging group of patients with limited remaining alternatives.

The second study out of the Daniel den Hoed Cancer Center in Rotterdam, part of the Erasmus Medical Centerthe largest of the eight university medical centers in The Netherlandsreports on the center's experience over the last five years using the CyberKnife System to treat 56 patients with metastatic lung tumors, several of whom had two or more tumors. 24 of these patients had central tumors, which demand the highest degree of accuracy and precision in treatment. Leveraging the CyberKnife System's real-time tumor tracking and automatic radiation beam correction, researchers in Rotterdam were able to deliver high doses of radiation in just a few fractions to achieve high rates of tumor control with low rates of side effects regardless of tumor location.

In addition, data from two centers in Italythe Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) and the G.B. Morgagni-L. Pierantoni Hospital in Forli, Italydemonstrate that intensity-modulated radiotherapy (IMRT) using the TomoTherapy system can provide additional treatment options for patients with advanced stage lung cancer when combined with systemic chemotherapy. The TomoTherapy system allows for sparing of normal tissue while still providing coverage of wide areas of diffuse disease typically seen in advanced stage lung cancer.

The World Conference on Lung Cancer was hosted by the International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer and thoracic malignancies. For more information, please visit http://www.2011worldlungcancer.org/.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company. Accuray develops, manufactures and sells personalized, best-in-class treatment solutions that revolve around the patient. Accuray's game-changing technologies the CyberKnife System and TomoTherapy Systems set the standard of care with the aim of helping patients live longer, better lives. To date, more than 200,000 patients worldwide have been treated using the company's technologies and more than 550 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical experience, clinical data, clinical applications, clinical results and combinations of treatments are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on May 10, 2011 and our other filings with the Securities and Exchange Commission.. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan S. Thomson, Ph.D.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869

SOURCE Accuray Incorporated


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES